keyword
MENU ▼
Read by QxMD icon Read
search

Cannabidiol

keyword
https://www.readbyqxmd.com/read/29346673/commentary-on-the-potential-of-cannabidiol-treatment-for-cannabis-users-with-recent-onset-psychosis
#1
Philip McGuire, Amir Englund, Sagnik Bhattacharyya
No abstract text is available yet for this article.
January 13, 2018: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/29344464/cannabinoids-in-the-treatment-of-epilepsy-hard-evidence-at-last
#2
REVIEW
Emilio Perucca
The interest in cannabis-based products for the treatment of refractory epilepsy has skyrocketed in recent years. Marijuana and other cannabis products with high content in Δ(9) - tetrahydrocannabinol (THC), utilized primarily for recreational purposes, are generally unsuitable for this indication, primarily because THC is associated with many undesired effects. Compared with THC, cannabidiol (CBD) shows a better defined anticonvulsant profile in animal models and is largely devoid of adverse psychoactive effects and abuse liability...
December 2017: Journal of Epilepsy Research
https://www.readbyqxmd.com/read/29338068/single-and-combined-effects-of-plant-derived-thc-cbd-and-synthetic-win-55-212-cannabinoids-on-cognition-and-cannabinoid-associated-withdrawal-signs-in-mice
#3
Alyssa M Myers, Patrick B Siegele, Jeffrey D Foss, Ronald F Tuma, Sara Jane Ward
BACKGROUND AND PURPOSE: It has been suggested that the non-euphorogenic phytocannabinoid cannabidiol (CBD) can ameliorate adverse effects of delta-9-tetrahydrocannabinol (THC). We determined whether CBD ameliorates cognitive deficits and withdrawal signs induced by cannabinoid CB1/CB2 receptor agonists or produces these pharmacological effects on its own. EXPERIMENTAL APPROACH: The effects of THC or the CB1/CB2 receptor full agonist WIN55212 (WIN) alone, CBD alone, or their combination were tested across a range of doses...
January 16, 2018: British Journal of Pharmacology
https://www.readbyqxmd.com/read/29337440/-addictions
#4
Jacques Besson, Jeremy Grivel, Alexander Tomei, Mélina Andronicos, Daniele Zullino, Gabriel Thorens, Stergios Tsartsalis, Isabelle Gothuey, Monique Séguin
This year, the actuality for addictions in this edition addresses four points. The disease model of addiction is criticized by the cognitive neurosciences which need to consider the agentivity of the persons. Regarding the societal actuality, clinical pharmacology review of cannabidiol presents an update on legal cannabis. The suicidality of excessive gamblers may be prevented specifically. Addiction and first psychotic episodes need an integrated care.
January 10, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29314377/cannabidiol-for-drug-resistant-seizures-in-the-dravet-syndrome
#5
Craig Mellis
No abstract text is available yet for this article.
January 2018: Journal of Paediatrics and Child Health
https://www.readbyqxmd.com/read/29313138/do-psychoactive-drugs-have-a-therapeutic-role-in-compulsivity-studies-on-schedule-induced-polydipsia
#6
Elena Martín-González, Ángeles Prados-Pardo, Santiago Mora, Pilar Flores, Margarita Moreno
RATIONALE: Clinical studies have shown that some psychoactive recreational drugs have therapeutic applications in anxiety, depression, and schizophrenia. However, to date, there are few studies on the therapeutic potential efficacy of recreational drugs in compulsive neuropsychiatric disorders. OBJECTIVES: We explored the therapeutic potential of different psychoactive and psychedelic drugs in a preclinical model of compulsive behavior. METHODS: Outbred male Wistar rats were selected as either high (HD) or low (LD) drinkers according to their behavior in schedule-induced polydipsia (SIP)...
January 8, 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29307505/practical-considerations-in-medical-cannabis-administration-and-dosing
#7
REVIEW
Caroline A MacCallum, Ethan B Russo
Cannabis has been employed medicinally throughout history, but its recent legal prohibition, biochemical complexity and variability, quality control issues, previous dearth of appropriately powered randomised controlled trials, and lack of pertinent education have conspired to leave clinicians in the dark as to how to advise patients pursuing such treatment. With the advent of pharmaceutical cannabis-based medicines (Sativex/nabiximols and Epidiolex), and liberalisation of access in certain nations, this ignorance of cannabis pharmacology and therapeutics has become untenable...
January 4, 2018: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/29302228/cannabis-cannabinoids-and-health
#8
Genevieve Lafaye, Laurent Karila, Lisa Blecha, Amine Benyamina
Cannabis (also known as marijuana) is the most frequently used illicit psychoactive substance in the world. Though it was long considered to be a "soft" drug, studies have proven the harmful psychiatric and addictive effects associated with its use. A number of elements are responsible for the increased complications of cannabis use, including the increase in the potency of cannabis and an evolution in the ratio between the two primary components, Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (toward a higher proportion of Δ9-THC), Synthetic cannabinoid (SC) use has rapidly progressed over the last few years, primarily among frequent cannabis users, because SCs provide similar psychoactive effects to cannabis...
September 2017: Dialogues in Clinical Neuroscience
https://www.readbyqxmd.com/read/29287930/ptl401-a-new-formulation-based-on-pro-nano-dispersion-technology-improves-oral-cannabinoids-bioavailability-in-healthy-volunteers
#9
Jacob Atsmon, Irina Cherniakov, Dvora Izgelov, Amnon Hoffman, Abraham J Domb, Lisa Deutsch, Frederic Deutsch, Daphna Heffetz, Hagit Sacks
There is growing clinical interest in developing and commercializing pharmaceutical-grade cannabinoid products, containing primarily tetrahydrocannabinol (THC) and cannabidiol (CBD). The oral bioavailability of THC and CBD is very low due to extensive "first pass" metabolism. A novel oral THC and CBD formulation, PTL401, utilizing an advanced self-emulsifying oral drug delivery system, was designed to circumvent the "first pass" effect. In this study, the bioavailability of THC and CBD from the PTL401 capsule was compared with similar doses from a marketed reference oromucosal spray (Sativex®)...
December 26, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29285522/cannabidiol-does-not-convert-to-%C3%AE-9-tetrahydrocannabinol-in-an-in-vivo-animal-model
#10
Louise Wray, Colin Stott, Nicholas Jones, Stephen Wright
Introduction: Cannabidiol (CBD) can convert to Δ9-tetrahydrocannabinol (THC) in vitro with prolonged exposure to simulated gastric fluid; however, in vitro conditions may not be representative of the in vivo gut environment. Using the minipig, we investigated whether enteral CBD converts to THC in vivo. Materials and Methods: Synthetic CBD (100 mg/mL) was administered orally in a sesame oil formulation twice daily to minipigs (N=3) in 15 mg/kg doses for 5 consecutive days. Blood samples were taken before and 1, 2, 4, and 6 h after morning doses on Days 1 and 5...
2017: Cannabis and Cannabinoid Research
https://www.readbyqxmd.com/read/29274332/abnormal-cannabidiol-confers-cardioprotection-in-diabetic-rats-independent-of-glycemic-control
#11
Asmaa I Matouk, Ashraf Taye, Mohamed A El-Moselhy, Gehan H Heeba, Abdel A Abdel-Rahman
Chronic GPR18 activation by its agonist abnormal cannabidiol (trans-4-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol; abn-cbd) improves myocardial redox status and function in healthy rats. Here, we investigated the ability of abn-cbd to alleviate diabetes-evoked cardiovascular pathology and the contribution of GPR18 to this effect. Four weeks after diabetes induction by streptozotocin (STZ, 55mg/kg; i.p), male Wistar rats received abn-cbd, the GPR18 antagonist (1,3-dimethoxy-5-methyl-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-,cyclohexen-1-yl]benzene;O-1918), their combination (100µg/kg/day, i...
December 20, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29262425/quantitative-determination-of-%C3%AE-9-thc-cbg-cbd-their-acid-precursors-and-five-other-neutral-cannabinoids-by-uhplc-uv-ms
#12
Yan-Hong Wang, Bharathi Avula, Mahmoud A ElSohly, Mohamed M Radwan, Mei Wang, Amira S Wanas, Zlatko Mehmedic, Ikhlas A Khan
Cannabinoids are a group of terpenophenolic compounds in the medicinal plant Cannabis sativa (Cannabaceae family). Cannabigerolic acid, Δ9-tetrahydrocannabinolic acid A, cannabidiolic acid, Δ9-tetrahydrocannabinol, cannabigerol, cannabidiol, cannabichromene, and tetrahydrocannabivarin are major metabolites in the classification of different strains of C. sativa. Degradation or artifact cannabinoids cannabinol, cannabicyclol, and Δ8-tetrahydrocannabinol are formed under the influence of heat and light during processing and storage of the plant sample...
December 20, 2017: Planta Medica
https://www.readbyqxmd.com/read/29241357/cannabidiol-cbd-as-an-adjunctive-therapy-in-schizophrenia-a-multicenter-randomized-controlled-trial
#13
Philip McGuire, Philip Robson, Wieslaw Jerzy Cubala, Daniel Vasile, Paul Dugald Morrison, Rachel Barron, Adam Taylor, Stephen Wright
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. METHOD: In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 mg/day; N=43) or placebo (N=45) alongside their existing antipsychotic medication. Participants were assessed before and after treatment using the Positive and Negative Syndrome Scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), the Global Assessment of Functioning scale (GAF), and the improvement and severity scales of the Clinical Global Impressions Scale (CGI-I and CGI-S)...
December 15, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/29240420/iodine-promoted-aromatization-of-p-menthane-type-phytocannabinoids
#14
Federica Pollastro, Diego Caprioglio, Patrizia Marotta, Aniello Schiano Moriello, Luciano De Petrocellis, Orazio Taglialatela-Scafati, Giovanni Appendino
Treatment with iodine cleanly converts various p-menthane-type phytocannabinoids and their carboxylated precursors into cannabinol (CBN, 1a). The reaction is superior to previously reported protocols in terms of simplicity and substrate range, which includes not only tricyclic tetrahydrocannabinols such as Δ9-THC (2a) but also bicyclic phytocannabinoids such as cannabidiol (CBD, 3a). Lower homologues from the viridin series (2c and 3c, respectively) afforded cannabivarin (CBV), a non-narcotic compound that, when investigated against a series of ionotropic (thermo-TRPs) biological end-points of phytocannabinoids, retained the submicromolar TRPA1-activating and TRPM8-inhibiting properties of CBN, while also potently activating TRPV2...
December 14, 2017: Journal of Natural Products
https://www.readbyqxmd.com/read/29238589/cannabidiol-restores-intestinal-barrier-dysfunction-and-inhibits-the-apoptotic-process-induced-by-clostridium-difficile-toxin-a-in-caco-2-cells
#15
Stefano Gigli, Luisa Seguella, Marcella Pesce, Eugenia Bruzzese, Alessandra D'Alessandro, Rosario Cuomo, Luca Steardo, Giovanni Sarnelli, Giuseppe Esposito
Background: Clostridium difficile toxin A is responsible for colonic damage observed in infected patients. Drugs able to restore Clostridium difficile toxin A-induced toxicity have the potential to improve the recovery of infected patients. Cannabidiol is a non-psychotropic component of Cannabis sativa, which has been demonstrated to protect enterocytes against chemical and/or inflammatory damage and to restore intestinal mucosa integrity. Objective: The purpose of this study was to evaluate (a) the anti-apoptotic effect and (b) the mechanisms by which cannabidiol protects mucosal integrity in Caco-2 cells exposed to Clostridium difficile toxin A...
December 2017: United European Gastroenterology Journal
https://www.readbyqxmd.com/read/29237190/determination-of-acid-and-neutral-cannabinoids-in-extracts-of-different-strains-of-cannabis-sativa-using-gc-fid
#16
Elsayed A Ibrahim, Waseem Gul, Shahbaz W Gul, Brandon J Stamper, Ghada M Hadad, Randa A Abdel Salam, Amany K Ibrahim, Safwat A Ahmed, Suman Chandra, Hemant Lata, Mohamed M Radwan, Mahmoud A ElSohly
Cannabis (Cannabis sativa L.) is an annual herbaceous plant that belongs to the family Cannabaceae. Trans-Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) are the two major phytocannabinoids accounting for over 40% of the cannabis plant extracts, depending on the variety. At the University of Mississippi, different strains of C. sativa, with different concentration ratios of CBD and Δ9-THC, have been tissue cultured via micropropagation and cultivated. A GC-FID method has been developed and validated for the qualitative and quantitative analysis of acid and neutral cannabinoids in C...
December 13, 2017: Planta Medica
https://www.readbyqxmd.com/read/29225539/anticonvulsant-effects-of-cannabidiol-in-dravet-syndrome
#17
COMMENT
Mohamad Koubeissi
No abstract text is available yet for this article.
September 2017: Epilepsy Currents
https://www.readbyqxmd.com/read/29218644/cardiovascular-complications-of-marijuana-and-related-substances-a-review
#18
REVIEW
Amitoj Singh, Sajeev Saluja, Akshat Kumar, Sahil Agrawal, Munveer Thind, Sudip Nanda, Jamshid Shirani
The recreational use of cannabis has sharply increased in recent years in parallel with its legalization and decriminalization in several countries. Commonly, the traditional cannabis has been replaced by potent synthetic cannabinoids and cannabimimetics in various forms. Despite overwhelming public perception of the safety of these substances, an increasing number of serious cardiovascular adverse events have been reported in temporal relation to recreational cannabis use. These have included sudden cardiac death, vascular (coronary, cerebral and peripheral) events, arrhythmias and stress cardiomyopathy among others...
December 7, 2017: Cardiology and Therapy
https://www.readbyqxmd.com/read/29214639/cannabinoids-for-epilepsy-what-do-we-know-and-where-do-we-go
#19
REVIEW
Martin J Brodie, Elinor Ben-Menachem
Over the past decade there has been an increasing interest in using cannabinoids to treat a range of epilepsy syndromes following reports of some remarkable responses in individual patients. The situation is complicated by the fact that these agents do not appear to work via their attachment to endogenous cannabinoid receptors. Their pharmacokinetics are complex, and bioavailability is variable, resulting in difficulty in developing a suitable formulation for oral delivery. Drug interactions also represent another complication in their everyday use...
December 6, 2017: Epilepsia
https://www.readbyqxmd.com/read/29202305/development-of-a-simple-and-sensitive-liquid-chromatography-triple-quadrupole-mass-spectrometry-lc-ms-ms-method-for-the-determination-of-cannabidiol-cbd-%C3%AE-9-tetrahydrocannabinol-thc-and-its-metabolites-in-rat-whole-blood-after-oral-administration-of-a-single
#20
Federica Palazzoli, Cinzia Citti, Manuela Licata, Antonietta Vilella, Letizia Manca, Michele Zoli, Maria Angela Vandelli, Flavio Forni, Giuseppe Cannazza
The investigation of the possible conversion of cannabidiol (CBD) into Δ9-tetrahydrocannabinol (THC) in vivo after oral administration of CBD is reported herein since recent publications suggested a rapid conversion in simulated gastric fluid. To this end, single high dose of CBD (50mg/kg) was administered orally to rats and their blood was collected after 3 and 6h. A highly sensitive and selective LC-MS/MS method was developed and fully validated in compliance with the Scientific Working Group of Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology...
November 28, 2017: Journal of Pharmaceutical and Biomedical Analysis
keyword
keyword
1686
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"